Benzinga · Feb 2, 2026
PB
NASDAQ · PBMWW
Psyence Biomedical Ltd. Warrant
Healthcare · Biotechnology
$0.02
Down-$0.00 (-19.75%)
Updated Aug 13, 2026, 11:08 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.72K
- P/E ratio
- -0.19
- Dividend yield
- 0.00%
- 52-week range
- $0.02 – $0.09
- Volume
- 61.35K
- Avg. volume
- 59.67K
Price performance
PBMWW price history
1M range · 20 trading sessions · Daily adjusted prices
PBMWW closed at $0.02 after 20 trading sessions, up 19.00% for the selected period.
- Last close
- $0.02
- Period change
- +19.00%
- Period low
- $0.02
- Period high
- $0.04
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $0.022 | $0.0239 | $0.0201 | $0.0238 | 61.35K |
| Aug 11, 2026 | $0.023 | $0.0248 | $0.023 | $0.023 | 929.61 |
| Aug 7, 2026 | $0.0242 | $0.0259 | $0.0224 | $0.0258 | 52.8K |
| Aug 6, 2026 | $0.0238 | $0.0268 | $0.0238 | $0.0266 | 1.7K |
| Aug 5, 2026 | $0.0261 | $0.0261 | $0.021 | $0.0243 | 37.67K |
| Aug 4, 2026 | $0.0322 | $0.035 | $0.0322 | $0.035 | 1.2K |
| Aug 3, 2026 | $0.029 | $0.035 | $0.029 | $0.035 | 4.7K |
| Jul 31, 2026 | $0.0344 | $0.0344 | $0.0344 | $0.0344 | 749 |
| Jul 30, 2026 | $0.0289 | $0.0346 | $0.0289 | $0.0345 | 366.9 |
| Jul 29, 2026 | $0.0261 | $0.0348 | $0.0261 | $0.0348 | 532.62 |
| Jul 28, 2026 | $0.0253 | $0.035 | $0.0253 | $0.0349 | 393.72 |
| Jul 27, 2026 | $0.0319 | $0.0348 | $0.0318 | $0.0347 | 12.13K |
| Jul 24, 2026 | $0.0234 | $0.0318 | $0.0234 | $0.0318 | 1.9K |
| Jul 23, 2026 | $0.023 | $0.0319 | $0.023 | $0.0319 | 1.87K |
| Jul 22, 2026 | $0.0303 | $0.0303 | $0.0303 | $0.0303 | 318.6 |
| Jul 21, 2026 | $0.0305 | $0.0305 | $0.0231 | $0.0301 | 3.71K |
| Jul 20, 2026 | $0.0298 | $0.032 | $0.0298 | $0.0313 | 86.99K |
| Jul 17, 2026 | $0.0243 | $0.0299 | $0.0229 | $0.0299 | 15.71K |
| Jul 16, 2026 | $0.0246 | $0.0246 | $0.0245 | $0.0245 | 200 |
| Jul 15, 2026 | $0.02 | $0.02 | $0.02 | $0.02 | 1K |
Latest PBMWW news
The latest Smart Investors Daily articles mentioning PBMWW.
Stock researchCompany · Overview
PBMWW research
Overview
Company profile and research snapshot.
Company profile
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Jan 30, 2026
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
Yahoo · Nov 12, 2025
Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Psyence BioMed (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that, through its strategic investment in PsyLabs, it is now the only publicly listed psychedelics company with active operations and manufacturing capabilities based in Africa – the natural and original source of ibogaine. Derived from the Tabernanthe ibo
GlobeNewswire Inc. · Nov 3, 2025
Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment
Psyence BioMed made a $3.5 million follow-on investment in PsyLabs, a leading producer of psychedelic pharmaceutical ingredients, to secure a sustainable and ethical supply chain for its clinical research programs in mental health therapies.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
